2020 Scientific Sessions

The Low-Risk TAVR Patient: Considerations in 2020

This activity is supported by an unrestricted educational grant from Medtronic. No in-kind commercial support was received.
Critical Review of the Evidence: Bicuspid in Low-Risk Patients
John K. Forrest, MD, Yale University, New Haven, CT
Case Reviews From Low Risk Bicuspid Trial
Stanley J. Chetcuti, M.D., FSCAI, The University of Michigan, Ann Arbor, MI
How to Optimize Coronary Intervention Therapy in TAVR
James E. Harvey, M.D., FSCAI, WellSpan York Hospital, Red Lion, PA
See more of: Satellite Sessions